This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
The Congressional Oversight Panel's Valuation of the TARP Warrants (A)
Baldwin, Carliss Y.Case HBS-210035-EFinanceThe Congressional Oversight Panel wants to value the warrants issued to the government in connection with the TARP investments of 2008, in order to increase the transparency of options repurchases. The case describes the methodology used to value the warrants. Students have the opportunity to value warrants issued by 10 of the largest banks and to evaluate whether the Black-Scholes model can be used to value these very long-lived 10 options. Can ...Starting at €8.20
-
Evaluating M&A Deals--Equity Consideration
Baldwin, Carliss Y.Case HBS-208077-EFinanceWhat the acquiring company pays for a target in a merger or acquisition is called "consideration." Consideration can be in the form of cash, shares, or a combination of the two. Lays out the basic mechanics of equity consideration. Derives formulas for thStarting at €8.20
-
Evaluating M&A Deals: Accretion vs. Dilution of Earnings-per-share
Baldwin, Carliss Y.Case HBS-208059-EFinanceWhen discussing the pros and cons of an acquisition, practitioners often talk about the impact of the deal on the buyer's earnings-per-share (eps). An acquisition is said to be "accretive" if the buyer's eps goes up post-deal; it is "dilutive" if the buyeStarting at €8.20
-
PepsiCo's Bid for Quaker Oats (C)
Baldwin, Carliss Y.Case HBS-209070-EFinanceThird in a series of PepsiCo's bid for Quaker Oats. Describes the auction for Quaker Oats including terms of the bids. After winning the auction, Coke's stock price fell dramatically. Coke's Board then refused to approve the deal and withdrew. Quaker then approached Pepsi, the losing bidder, and asked them to submit another bid. The case can be used to teach the mechanics of collared consideration, announcement effects, the prerogatives of a boar...Starting at €5.74
-
Evaluating M&A Deals--Announcement Effects, Risk Arbitrage and Event Risk
Baldwin, Carliss Y.Case HBS-208103-EFinanceThe announcement of merger or acquisition conveys new information to the capital markets. This note describes how the stock prices of a Buyer and Target behave after the announcement of a deal. First, for an all-stock deal that is certain to go through, the note defines accouchement effects and describes the fundamental arbitrage relationship between Target and Buyer stock prices. It shows how post-announcement prices may be used to infer the mar...Starting at €8.20
-
Massey-Ferguson Ltd.--1980 (Spanish version)
Baldwin, Carliss Y.; Mason, Scott P.; Hughes, Jennifer H.Case HBS-202S12FinanceMassey Ferguson began fiscal year 1981 in default on $2.5 billion of outstanding debt. The company's future depends on the ability of lenders, the governments of Canada and Ontario, and management, to agree on a refinancing plan. The case reviews Massey's performance and position in the industry and raises questions about the company's ability to compete in the long run. Provides information on the firm's claimants in order to focus students on t...Starting at €8.20
-
Paramount Equipment, Teaching Note
Baldwin, Carliss Y.; Wang, WeiTeaching Note HBS-914558-EFinanceTeaching Note for Product #914557Starting at €0.00
-
Mellon Financial and The Bank of New York, Teaching Note
Taliaferro, Ryan D.; Baldwin, Carliss Y.Teaching Note HBS-211054-EFinanceTeaching Note for 208129.Starting at €0.00
-
Apple, Einhorn, and iPrefs
Baldwin, Carliss Y.; Feit, Hanoch; Minasian, Edward A.; Van Buren, BrandonCase HBS-215037-EFinanceIn March 2013, Apple Inc. has a very large cash balance and is under pressure to return cash to shareholders. Hedge fund manager David Einhorn thinks Apple can "unlock value" by issuing perpetual preferred stock, dubbed iPrefs. Henry Blodget, CEO of The BStarting at €8.20
-
Roche's Acquisition of Genentech
Baldwin, Carliss Y.; Becker, Bo; Dessain, VincentCase HBS-210040-EFinanceFranz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, tStarting at €8.20